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Abstract 
Background: Familial combined hyperlipidemia or FCHL is one of the most common genetic 
causes of hyperlipidemia and is associated with elevation of cholesterol, triglycerides or both, 
and increased serum apolipoprotein B (apoB). Linkage analysis and next generation sequencing 
have been successfully used for identifying rare genetic variants that have moderate-to large 
effects.  
Methods: We characterized a large pedigree from a proband identified following recruitment 
into the MASHAD study, in northeast Iran, with FCHL accompanied by early-onset coronary 
artery disease. We used linkage analysis for several candidate regions in previous studies such as 
1q21-23, 11q23 and 8p, and then whole-exome sequencing to identify the disease-associated 
gene in this family 
Results: we identified a novel variant in the USF1 gene, leading to a substitution of a tryptophan 
for arginine at position 196. Arg196Trp co-segregated in all the affected family members in this 
pedigree with clinical syndrome, and was not found in any  unaffected family members of this 
pedigree, nor in unrelated controls. 
Conclusions: We speculate that this mutation [Arg196Trp] in the USF1 gene might be 
associated with FCHL and early-onset coronary heart disease in this family. However, the 
substantial mechanism requires further investigation. These finding indicate that USF1 plays an 
important role in the biological pathways associated with lipid metabolism 
Key words: Familial Combined Hyperlipidemia, FCHL, Cardiovascular Disease, Cholesterol, 
Triglycerides 
Introduction 
Familial combined Hyperlipidemia (FCHL) is the most common genetic and metabolic form of 
hyperlipidemia with prevalence of 0.5% to 2% worldwide and about 10% of these patients suffer 
from cardiovascular disease. This number has increased by approximately 11.3% in young 
survivors of myocardial infarction (MI) and by 40% among all the people who survived an MI 
(1-4).  Based on previous studies about 3.5 million people in Europe and 7.2 million people in 
the US are affected by this disorder(5, 6). Biochemically, FCHL is associated with increased 
levels of triglyceride, total cholesterol, or both, and increased levels of VLDL, LDL, decreased 
HDL, and increased apo B level(1, 7, 8). Based on a combination of past and recent definitions, 
FCHL is now been recognized as a common metabolic disorder, and is characterized in a family 
by an increased serum triglyceride and LDL in two members of a family accompanied by 
increased risk of premature coronary artery disease(4, 9). FCHL is genetically complex; in 
addition to the role of environmental factors, the FCHL is genetically heterogeneous(10, 11).  
Three important genetic loci for FCHL have been identified: 1q21-23, apolipoprotein A-I/C-
III/A-IV cluster on chromosome 11 and lipoprotein lipase (LPL) gene on 8p that in several 
different studies had significant LOD scores with FCHL. Pajukanta et al have reported a linkage 
between FCHL and chromosome 1q markers in a Finnish families(12, 13). 
Next-generation sequencing (NGS) has had an important role in identifying  the genes and rare 
variants in a huge number of diseases with moderate-to-large effects(14). NGS  can be applied 
for identification of rare mutations in families with specific extreme phenotypes  with high-
speed, high-power, and low-cost (15, 16). The linkage analysis technique has been used for many 
years as the first method of gene discovery and genetic mapping of Mendelian and complex traits 
which have a familial aggregation (17). Linkage analysis can be used in conjunction with NGS 
filtering approaches as an important and powerful technique for discovering of some genes 
involved in diseases etiology(18, 19). In this study, linkage analysis and whole-exome 
sequencing were used to investigate the members of a large family, with a familial pattern of 
FCHL associated with coronary artery disease. 
Material and methods 
1. Study population 
The protocol of this study was approved by the local ethics committee of Mashhad University of 
Medical Sciences and all study participants in present study signed consent form. We identified a 
family with a recurring familial pattern of FCHL from a cohort as name MASHAD study in 
northeast Iran, Mashhad who they had an unusual constellation of juvenile-onset FCHL 
accompanied by an early-onset coronary artery disease and elevated fasting serum triglyceride 
and cholesterol levels that this was accordance with FCHL diagnosis based on 2016 ESC/EAS 
Guidelines for the Management of Dyslipidemias. This large pedigree was notable for having 
several affected members with FCHL with what appeared to be an autosomal dominant 
inheritance pattern.  Also there were several people in this pedigree who did not have these traits 
(FIG 1). In this family affected members had a familial clustering and could trace their descent 
from a common ancestor, that suggested that the affected family members had an autosomal 
dominant pattern. After evaluation these family members, we collected clinical and laboratory 
data for all members of this family who were older than 30 years of age. Also we collected 5 mL 
blood contain EDTA anticoagulant and then, genomic DNA was extracted. For biochemical 
analysis we collected 5 mL blood without anticoagulant and after 30 minutes we separated serum 
with centrifuge at 5000 RPM for 10 minutes at room temperature. 5cc blood was obtained, and 
genomic DNA was extracted. Also we collected 5cc blood from 100 healthy people over 60 
years of age for later studies. 
STR markers genotyping and linkage analysis 
DNA samples from 25 living family members were used for linkage studies, including 12 family 
member’s diagnosed for FCHL disease and 13 unaffected family members. We performed a 
parametric analysis of linkage with STR markers for 1q21-23, 11q21 and 8P using samples 
obtained from affected members. Primer sequences are present in UCSC genome browser. A 
panel of two different STR markers were genotyped for lq21-23 locus on chromosome 1 
including D1S104 and D1S1677. We used the D11S4127 marker for apolipoprotein A-I/C-III/A-
IV on chromosome 11 and D8S282 marker for LPL gene that is a candidate gene for FCHL 
based on past studies. Subjects were considered to affected, or unknown to ignore the reduced 
penetrance effect.  Polymerase chain reactions (PCR) were used under standard conditions 
optimized for each 4 markers. Details of conditions and concentrations reactions can be provided 






Whole exome sequencing  
DNA from the index patient from this family was sequenced for mutations by using the WES 
technique. Whole Exome Sequencing was used to enrich all exons of protein-coding regions as 
well as some important other genomic regions. NGS was performed using an Illumina Sequencer 
to sequence approximately 100 million reads. In total, this platform sequenced >95% of the 
targeted regions with an acceptable sensitivity of >99%. In this approach, duplications, micro-
insertion/deletions, and point mutations can be detected. After this we used bioinformatics 
analysis for sequencing results by using international databases and standard bioinformatics 
software then, filtration of raw data was performed, to remove common variants that are exist in 
reference genomes. We also applied filters against some published data in databases and those 
variants with novelty that had a deleterious effect on proteins, tissue expression were selected for 
more investigation. 
Variant Validation Studies with sanger sequencing  
After WES annotation we found a mis-sense mutation in exon 8 USF1 gene which is reported to 
be an important gene for susceptibility to FCHL in previous studies. We confirmed this variant in 
the index patient by PCR technology and sanger sequencing technique (PCR primers and their 
characteristics are shown in table 1). Also we carried out segregation studies in other members of 
this family who were not applied for WES and polymerase chain reaction was used for 
sequencing target regions especially the variants of interest (FiG2). The PCR was performed 
with mastermix solutions contain PCR buffer, MgCL2, deoxyribonucleotide triphosphates, Taq 
DNA po-lymerase and 10 pmol of each primer, 100 ng ge-nomic DNA in a volume of 25 μl. we 
set up thermocycler for an initial denaturation at 95 °C for 5 min in step 1 followed by 35 cycles 
in step 2 for an denaturation  at 95 °C for 1 min, annealing at 59 °C for 45 sec, an extension at 72 
°C for 1 min and a final extension in step 3 at 72 °C for 10 min. Then the products of  PCR were 
run and separate on 1% agarose gel and visualized with green viewer. The amplified products 
were sequenced by sanger sequencing technique and data were analyzed with the help of Snap 
gene software. In addition, we tested 100 healthy people in over 60 years of age for this variant 
from general population of this area. 
Results 
Study population 
The clinically characterized members of this family included 13 affected family members with 
FCHL. All 13 affected family members had CAD at a mean (±SE) age of 40 ±5 years. All the 
affected family members had a serum total cholesterol >240 mg/dL, LDL> 160 mg/dL, TG>120 
mg/dL and apoB > 120 mg/dL and based on 2016 ESC/EAS Guidelines for the Management of 
Dyslipidaemias they met the standard definition of a metabolic syndrome called FCHL (Table 2).  
Linkage study  
We carried out a parametric analysis of linkage with STR markers for 1q21-23, 11q21 and 8P 
using genotypes obtained from affected and non-affected members of this pedigree. The 
condition was considered as an autosomal dominant trait. Analysis of linkage showed significant 
evidence for of 1q21-23 linked to FCHL patients. The maximum LOD score was 3.05 and other 
loci showed a LOD score less than 1.0. linkage analysis for 1q21-23 in this pedigree represented 
a founder mutation. No individual in this family was homozygous for this locus. The PCR 
conditions for STR markers are shown in Table 3 
Whole-Exome Sequencing and validation using sanger sequencing 
With filtration raw data from WES in the index patient, removing common SNPs and other 
variants that were found in databases as non-pathogenic, we identified a rare protein-altering 
variants in the index patient in USF1 gene on chromosome 1 in 1q21-23 locus which was linked 
to FCHL in all affected members of this family. This mutation led to a substitution of tryptophan 
for arginine at position 196 of USF1 (p. Arg196Trp) (FIG3). segregation genotyping showed a 
cosegregation of this variant in all affected members. Also these variant was not found in healthy 
members of this pedigree.  
The Arginine 196 of the USF1 gene is highly conserved between orthologues and paralogues in 
some species including Ptroglodytes, Mmulatta, Fcatus, Mmusculus, Drerio and humans. (Fig4).  
We genotyped 100 ethnically healthy control from matched Iranians for Arg196Trp variant and 
this mutation was absent in all samples. This variant was not found in databases such as ExAC, 
gnomAD and iranome. Several programs such as Mutation taster, SIFT, PROVEAN, FATHMM, 
DANN and FATHMM-MKL predicted the variant to be damaging (Table 4).  
Discussion 
FCHL is one of the most common type of hyperlipidemia worldwide with increased risk of 
premature CHD and due to increased VLDL and LDL levels affected persons have an elevation 
of both cholesterol and triglycerides in the blood.  
 
The present study showed an association between a non-conservative mutation in the USF1 gene 
and FCHL patients associated with early-onset CHD in a family with an informative pedigree. 
The USF1 locus on 1q21-23 has been linked to FCHL and CHD in some previous studies(12, 20, 
21).  
USF1 is a transcription factor belong to the bHLH-Zip class, and the domain affected here is 
important for DNA binding and dimerization. The functional protein forms homo-dimers, or 
heterodimers with USF2 and through binding at distal E-box elements, activates the transcription 
of some target genes(22, 23). Thus some post translational modifications such as 
phosphorylation in USF1 can change transactivation activity(24). This gene can also play a role 
in chromatin barrier insulator function and protect euchromatin regions from heterochromatin-
induced gene silencing(25). Reduced expression of USF1 gene may lead to increased production 
and reduced metabolism of lipoproteins and plasma lipids because USF1 is involved in 
regulation of several genes of glucose and lipid metabolism(24). Whole-genome ChIP analysis 
identified 2518 binding sites for USF1 in HepG2 cells related to chromatin context which were 
strongly re correlated with expression level of some target genes and this suggested key roles for 
USF1 gene in transcription activation(26).  
We have found that FCHL is linked to 1q21-23 and this is confirmed in some previous linkage 
analysis such as studies done by Pajukanta et al (12, 27), Huertas-Vazquez (28) and Pei  et 
al(20).  Pei et al. investigated familial combined hyperlipidemia (FCHL) families from non-
isolated regions in China and Germany to investigate some evidence for linkage to a 
chromosome 1q locus and they observed a linkage between FCHL patients and 1q21–q23 locus 
(20). Pajukanta et al.  also carried out  a linkage analysis using several markers for 10 
chromosomal regions and they observed strongly support that a FCHL gene can be on 
chromosome 1q (12). It seemed that FCHL linkage to 1q21-23 is due to that 1q21-23 locus has 
several genes associated with lipid metabolism and usually based on recombination roles, it co-
segregates in affected members of a pedigree if the genes in this locus are a causes of the 
diseases. 
We carried out WES for one patients of this pedigree and data analysis with more focus on 1q21-
23 region showed a missense mutation in exon 8 of USF1 gene (p. Arg196Trp).  
Initially, Pajukanta et al. showed that FCHL is linked to the USF1 gene and they observed that 
FCHL is associated with a common haplotype contain non-coding SNPs within the USF1 
gene(27). It was also shown that individuals with the risky allele, have a lack of insulin-induced 
increase of USF1 expression in fat tissue and skeletal muscle. The USF1 gene has an important 
role in adipose tissue metabolism and through mediating the glucose-regulated expression of 
hormone-sensitive lipase (HSL) influences de novo lipogenesis by hormone-sensitive lipase, 
which is an important enzyme in the regulation of lipid source in adipose tissue(29, 30).  USF1 
also has an important role in transcription of fatty acid synthase which is involved in the 
synthesis of fatty acids and can plays an important role in the transcription of several 
apolipoproteins such as APOCIII, APOAII, and APOE, hepatic lipase, angiotensinogen,  
glucokinase, and ABCA1 (30, 31).  To date, 121 SNPs in the USF1 gene have been identified in 
the dbSNP database and only the rs4126997 T>C causes a non-synchronous mutation but data on 
functional studies and allele frequency are not available for this SNP. rs2073658 A>G in intron 7 
and rs3737787 C>T in the 3'-UTR are two functional SNP of USF1 gene that are in linkage 
disequilibrium which the minor allele is accompanied with normal expression of USF1 in fat 
tissues and human muscles but there is a loss of insulin-induced upregulation of USF1 mRNA 
and related target genes of USF1 gene and as a result insulin-mediated anti-lipolytic activity 
reduces(26, 32, 33).  
As USF1 gene has an important role in the regulation of numerous genes involved in the 
metabolism of lipids and glucose, non-responsive USF1 expression can adversely affect the 
metabolism of lipids and lipoproteins resulting in increased plasma lipids, thus USF1 is an ideal 
candidate gene for involvement with clinical features of FCHL and hyperlipidemia and some 
problems associated with CHD such as hypertension and we can say given that USF1 gene 
affects the complex lipid phenotype of familial combined hyperlipidemia. Arg196Trp mutation 
USF1 gene might be associated with FCHL and early-onset coronary heart disease in this family 
and can be a cause for related high triglycerides, ApoB, total cholesterol but for further 
confirmation it is necessary to undertake a functional study for this variant and can be later 
confirmed in controlled studies in animal models. 
Conclusion 
We have confirmed that 1q21-23 locus is linked to FCHL in an Iranian pedigree, and a new 
mutation in USF1 gene which is within this locus may be related with some clinical 
characteristics which is specified by elevation cholesterol, triglyceride, CAD. Therefore, our 
results indicate that USF1 gene plays an important role in some biologic pathways associated 
with lipid metabolism.  
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